IHH healthcare unit drags Daiichi Sankyo to court over Fortis Healthcare deal, claims 20 billion yen as damages
NTK is also seeking an injunction to prevent Daiichi from making defamatory remarks against it with respect to the aforesaid open offers, it noted.
New Delhi: A unit of Malaysia-based IHH Healthcare has sued Daiichi Sankyo for 20 billion yen for alleged interference in stake buy in Fortis Healthcare. Northern TK Venture Pte Ltd (NTK), a unit of IHH, has filed a claim in Tokyo District Court, seeking damages in excess of 20 billion Japanese yen from Daiichi Sankyo.
NTK's position is that Daiichi Sankyo has caused losses by preventing it from proceeding with the open offers in respect of the company and Malar Hospitals, Fortis Healthcare said in a regulatory filing. Fortis
NTK is also seeking an injunction to prevent Daiichi from making defamatory remarks against it with respect to the aforesaid open offers, it noted.
"The Claims filed by NTK against Daiichi Sankyo are tort claims premised on the latter's unlawful interference with NTK's trade or business, conspiracy of Daiichi Sankyo and other persons, malicious falsehood and defamation under the applicable substantive laws," IHH noted.
In November 2018, IHH had acquired, via a preferential allotment, a 31.17 per cent stake in Fortis by infusing a fresh capital of Rs 4,000 crore.
The IHH-Fortis deal is stuck due to a legal battle between Daiichi and the former promoters of Fortis Healthcare.
Read also: Proceed with Fortis open offer only after Delhi HC nod: SEBI to IHH
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd